Transient myeloproliferative disorder associated with trisomy 21: is a short course of chemotherapy indicated in patients with liver impairment and severe clinical problems?
Rizzari
C
C
Pediatric Department, University of Milan, Ospedale S. Gerardo, Monza, Italy. masera@xquasar.it
Malberti
R
R
Dell'Orto
M
M
Milani
M
M
Jankovic
M
M
Ferrari
E
E
Conter
V
V
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004314:Down Syndrome / Q000150:complications*; D004334:Drug Administration Schedule; D004417:Dyspnea / Q000209:etiology; D005334:Fever / Q000209:etiology; D006529:Hepatomegaly / Q000209:etiology* / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D018908:Muscle Weakness / Q000209:etiology; D009196:Myeloproliferative Disorders / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D009748:Nutrition Disorders / Q000209:etiology; D013163:Splenomegaly / Q000209:etiology
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D003630:Daunorubicin